The Eight Criteria Defining a Good Chemical Manufacturing Process

As pharmaceutical API projects advance from Development to Chemical Production, the primary objective of the Process Research and Development (R&D) chemists is a smooth transfer of a well-developed, safe, scalable, robust, and economical chemical process to their customers in Chemical Production. Since the definition of a Good Chemical Manufacturing Process differs widely amongst different departments and companies, we herein summarize eight useful process evaluation criteria, and then demonstrate our deployment according to the guiding principle “if it can be measured, then it can also be managed”, with the aim to offer chemists a helpful toolbox to effectively compare competing API synthesis routes.

[1]  Martin Poirier,et al.  Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. , 2004, Journal of medicinal chemistry.

[2]  Xudong Wei,et al.  Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis. , 2006, The Journal of organic chemistry.

[3]  Lawrence X. Yu.  Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[4]  Michael P. Ryan,et al.  Risk Assessment of Potentially Genotoxic Impurities within the Framework of Quality by Design , 2010 .

[5]  Roger A. Sheldon,et al.  The E Factor: fifteen years on , 2007 .

[6]  Martin Poirier,et al.  Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. , 2004, Journal of medicinal chemistry.

[7]  D. Enders,et al.  Organocatalytic cascade reactions as a new tool in total synthesis. , 2010, Nature chemistry.

[8]  Thomas Nicola,et al.  First Scale-Up to Production Scale of a Ring Closing Metathesis Reaction Forming a 15-Membered Macrocycle as a Precursor of an Active Pharmaceutical Ingredient , 2005 .

[9]  P. Bonneau,et al.  Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. , 2003, Angewandte Chemie.

[10]  Jinghua Xu,et al.  A novel one-step synthesis of 2-substituted 6-azaindoles from 3-amino-4-picoline and carboxylic esters. , 2005, The Journal of organic chemistry.

[11]  Xudong Wei,et al.  RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061. , 2008, Organic letters.

[12]  Paul T. Anastas,et al.  Green chemistry: present and future. , 2012, Chemical Society reviews.

[13]  Steven R. LaPlante,et al.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.

[14]  Phil S Baran,et al.  Aiming for the ideal synthesis. , 2010, The Journal of organic chemistry.

[15]  J. B. Hendrickson,et al.  Systematic synthesis design. IV. Numerical codification of construction reactions , 1975 .

[16]  B LengRonald,et al.  Holistic Route Selection , 2012 .

[17]  B. Trost,et al.  The atom economy--a search for synthetic efficiency. , 1991, Science.

[18]  Martin Poirier,et al.  NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent. , 2004, Journal of medicinal chemistry.

[19]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[20]  Fabrice Gallou,et al.  Organometallic methods for the synthesis and functionalization of azaindoles. , 2007, Chemical Society reviews.

[21]  Wei Zhang,et al.  Green techniques for organic synthesis and medicinal chemistry , 2012 .

[22]  Kari Rissanen,et al.  Calix[4]arene-functionalized naphthalene and perylene imide dyes. , 2002, Organic letters.

[23]  Jonathan D. Moseley,et al.  Kepner-Tregoe Decision Analysis as a Tool to Aid Route Selection. Part 1 , 2008 .

[24]  D. O'grady,et al.  A Review of the Use of Process Analytical Technology for the Understanding and Optimization of Production Batch Crystallization Processes , 2005 .

[25]  Paul A. Clarke,et al.  Combining pot, atom and step economy (PASE) in organic synthesis. Synthesis of tetrahydropyran-4-ones , 2007 .

[26]  Ivan Marziano,et al.  Critical assessment of pharmaceutical processes--A rationale for changing the synthetic route. , 2006, Chemical reviews.

[27]  Mathias Christmann,et al.  One-pot reactions accelerate the synthesis of active pharmaceutical ingredients. , 2011, Angewandte Chemie.

[28]  Martin Poirier,et al.  Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. , 2004, Organic letters.

[29]  Zadeo Cimarosti,et al.  Application of Quality by Design Principles to Support Development of a Control Strategy for the Control of Genotoxic Impurities in the Manufacturing Process of a Drug Substance , 2010 .

[30]  Krista L Dobo,et al.  Overview of Genotoxic Impurities in Pharmaceutical Development , 2009, International journal of toxicology.

[31]  Xudong Wei,et al.  Second-Generation Process for the HCV Protease Inhibitor BILN 2061: A Greener Approach to Ru-Catalyzed Ring-Closing Metathesis† , 2009 .